Can 5-methyltetrahydrofolate modify the phospholipid fatty acid pattern in cystic fibrosis pediatric patients?
Recent studies have reported an imbalance between n6 and n3 fatty acids (AA and DHA) in subjects with CF. Alterations in fatty acid amounts are present in CFTR-expressing tissues, plasma and in circulating blood cells. It has been reported that the correction of polyunsaturated fatty acid deficiency reversed the organ pathologies observed in CF knockout mice. We describe a CF child with an unusual clinical course presenting high molar percentage of DHA in plasma and red cells membrane during supplementation with 5-methyltetrahydrofolate and vitamin B12.
Scambi
Cinzia
C
Department of Clinical and Experimental Medicine, University of Verona, Chair of Internal Medicine B, 37134 Verona, Italy. cinzia.scambi@medicina.univr.it <cinzia.scambi@medicina.univr.it>
Guarini
Patrizia
P
De Franceschi
Lucia
L
Bambara
Lisa Maria
LM
D000328:Adult; D002918:Chymotrypsin / Q000032:analysis; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000378:metabolism*; D019587:Dietary Supplements; D004281:Docosahexaenoic Acids / Q000097:blood / Q000378:metabolism*; D043371:Fatty Acids, Omega-6 / Q000097:blood / Q000378:metabolism*; D005260:Female; D005492:Folic Acid / Q000494:pharmacology*; D006801:Humans; D007231:Infant, Newborn; D008745:Methylation; D008895:Milk, Human / Q000737:chemistry; D013763:Tetrahydrofolates / Q000494:pharmacology*
D043371:Fatty Acids, Omega-6; D013763:Tetrahydrofolates; D004281:Docosahexaenoic Acids; D005492:Folic Acid; D002918:Chymotrypsin; C005984:5-methyltetrahydrofolate